Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1225-1234

  Tanaka, Yoshihisa ^a   Shibata, Masa Aki ^a   Morimoto, Junji ^a   Otsuki, Yoshinori ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Antimetastasis; Antitumor; Mammary cancer; Phosphorylation; Sunitinib; VEGF; VEGFR

Indexed keywords

SUNITINIB; TYROSINE; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER SIZE; CANCER TISSUE; CELL DEATH; CONTROLLED STUDY; DENSITY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INOCULATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MICROVESSEL DENSITY; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BODY WEIGHT; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PYRROLES; TUMOR CELLS, CULTURED; TYROSINE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79956076053     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1996. CA Cancer J Clin 46: 5-27, 1996.
2. Kuroishi T and Tominaga S: Epidemiology of breast cancer. Jpn J Cancer Chemother 28: 168-173, 2001.
3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W and Sobue T: Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Jpn J Clin Oncol 39: 850-858, 2009.
4. Abrams TJ, Lee LB, Murray LJ, Pryer NK and Cherrington JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478, 2003.
5. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC and Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605, 2003. (Pubitemid 36857948)
6. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
7. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM and Pryer NK: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011-1021, 2003.
8. Christensen JG: A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18(Suppl 10): x3-10, 2007.
9. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
10. George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP and Demetri GD: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45: 1959-1968, 2009.
11. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP and Eisenhauer EA: A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22: 335-340, 2011.
12. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM and Miller KD: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816, 2008.
13. Socinski MA, Novello S, Brahmer JR, Rosell R, Sanchez JM, Belani CP, Govindan R, Atkins JN, Gillenwater HH, Pallares C, Tye L, Selaru P, Chao RC and Scagliotti GV: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26: 650-656, 2008. (Pubitemid 351264362)
14. Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S, Miyashita N, Moriwaki K and Hosick HL: New murine mammary tumor cell lines. In Vitro Cell Dev Biol 27A: 349-351, 1991.
15. Shibata MA, Morimoto J and Otsuki Y: Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 9: 16-27, 2002. (Pubitemid 34052850)
16. Shibata MA, Ito Y, Morimoto J and Otsuki Y: Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25: 1887-1898, 2004.
17. Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, Korsmeyer SJ and Green JE: Haploid loss of Bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. Embo J 18: 2692-2701, 1999. (Pubitemid 29233942)
18. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L and Maia AL: Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20: 863-871, 2010.
19. Kim SJ, Seo JH, Lee YJ, Yoon JH, Choi CW, Kim BS, Shin SW, Kim YH and Kim JS: Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells. Oncology 68: 204-211, 2005.
20. Neuchrist C, Erovic BM, Handisurya A, Steiner GE, Rockwell P, Gedlicka C and Burian M: Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111: 1834-1841, 2001.
21. Padera TP, Kuo AH, Hoshida T, Liao S, Lobo J, Kozak KR, Fukumura D and Jain RK: Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 7: 2272-2279, 2008.
22. Hiratsuka S, Watanabe A, Aburatani H and Mara Y: Tumour-mediated up-regulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375, 2006. (Pubitemid 44835111)
23. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, Lang RA and Pollard JW: A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One 4: e6562, 2009.
24. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA and King AG: Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 101: 1717-1723, 2009.
25. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239, 2009.
26. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Schultz L and Mikkelsen T: Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 99: 237-242, 2010.
27. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D and Casanovas O: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231, 2009.